Motor Function in α-Synuclein Mice Across Gut Microbiome Treatments
Motor function tests (beam, pole, adhesive removal, hindlimb clasping) comparing wild-type and α-synuclein overexpressing mice across 5 microbiome conditions: germ-free, antibiotics, SPF, ex-germ-free, and SCFA (n=105).
| # | Treatment | Genotype | Avg Beam cross time (sec) | Avg Pole descent time (sec) | Avg Adhesive removal time (sec) | Hindlimb score | + |
|---|---|---|---|---|---|---|---|
| 1 | SPF | WT | 6.32 | 4.87 | 2.29 | 0 | |
| 2 | SPF | WT | 4.79 | 4.33 | 5.58 | 0 | |
| 3 | SPF | WT | 4.23 | 6.25 | 5.18 | 0 | |
| 4 | SPF | WT | 5.37 | 7.44 | 3.8 | 0 | |
| 5 | SPF | WT | 4.89 | 4.77 | 1.58 | 1 | |
| 6 | SPF | WT | 5.29 | 6.64 | 1.31 | 0 | |
| 7 | SPF | WT | 5.8 | 6.86 | 1.56 | nd | |
| 8 | SPF | WT | 4.44 | 8.47 | 3.42 | nd | |
| 9 | SPF | WT | 3.51 | 4.92 | 2.53 | nd | |
| 10 | SPF | WT | 3.54 | 7.25 | 2.44 | nd | |
| 11 | SPF | ASO | 8.99 | 4.58 | 12.16 | 2 | |
| 12 | SPF | ASO | 8.93 | 8.48 | 2.38 | 1 | |
| 13 | SPF | ASO | 6.86 | 13.63 | 3.38 | 1 | |
| 14 | SPF | ASO | 6.36 | 9.34 | 1.41 | 1 | |
| 15 | SPF | ASO | 9 | 25.57 | 2.86 | 2 | |
| 16 | SPF | ASO | 8.24 | 9.19 | 7.36 | nd | |
| 17 | SPF | ASO | 5.31 | 14.59 | 2.19 | nd | |
| 18 | SPF | ASO | 9.06 | 18.97 | 11 | nd | |
| 19 | SPF | ASO | 9.43 | 12.08 | 22.28 | nd | |
| 20 | SPF | ASO | 7.12 | 6.32 | 16.78 | nd | |
| 21 | GF | WT | 6.676 | 4.89 | 3.56 | 0 | |
| 22 | GF | WT | 6.125 | 4.93 | 1.88 | 0 | |
| 23 | GF | WT | 4.895 | 2.18 | 3.53 | 0 | |
| 24 | GF | WT | 4.99 | 4.29 | 8.29 | 0 | |
| 25 | GF | WT | 9.92 | 3.01 | 1.26 | 0 | |
| 26 | GF | WT | 7.63 | 4.06 | 1.19 | 1 | |
| 27 | GF | WT | 1.98 | 8.6 | 1.14 | nd | |
| 28 | GF | WT | 2.62 | 6.09 | 3.22 | nd | |
| 29 | GF | WT | 6 | 2.18 | 1.81 | nd | |
| 30 | GF | WT | 3.71 | 4.29 | 3.03 | nd | |
| 31 | GF | WT | 3.04 | 3.01 | 4.78 | nd | |
| 32 | GF | ASO | 5.18 | 6.68 | 5.22 | 0 | |
| 33 | GF | ASO | 6.97 | 3.91 | 1.42 | 1 | |
| 34 | GF | ASO | 6.06 | 4.42 | 7.47 | 0 | |
| 35 | GF | ASO | 5.46 | 3.66 | 3.95 | 0 | |
| 36 | GF | ASO | 5.73 | 9.93 | 9.81 | 1 | |
| 37 | GF | ASO | 7.53 | 4.06 | 1.76 | 1 | |
| 38 | GF | ASO | 5.16 | 4.97 | 5 | nd | |
| 39 | GF | ASO | 3.82 | 3.49 | 6.47 | nd | |
| 40 | GF | ASO | 5.62 | 3.8 | 2.08 | nd | |
| 41 | GF | ASO | 3 | 8.65 | 5.13 | nd | |
| 42 | GF | ASO | 3.87 | 12.77 | 3.65 | nd | |
| 43 | Abx | WT | 2.56 | 2.91 | 2.42 | 1 | |
| 44 | Abx | WT | 4.06 | 9.26 | 1.2 | 0 | |
| 45 | Abx | WT | 8.18 | 5.79 | 15.56 | 0 | |
| 46 | Abx | WT | 7.68 | 5.38 | 5.63 | 0 | |
| 47 | Abx | WT | 4.81 | 4.62 | 3.64 | 0 | |
| 48 | Abx | WT | 5.47 | 5.58 | 9.52 | 0 | |
| 49 | Abx | WT | 6.32 | 11.96 | 7.12 | 0 | |
| 50 | Abx | WT | 6.82 | 5.94 | 6.01 | nd | |
| 51 | Abx | WT | 5.59 | 7.01 | 3.42 | nd | |
| 52 | Abx | WT | 4.3 | 7.38 | nd | nd | |
| 53 | Abx | WT | 3.94 | 3.84 | nd | nd | |
| 54 | Abx | WT | 4.04 | 6.96 | nd | nd | |
| 55 | Abx | WT | 4.07 | 7.52 | nd | nd | |
| 56 | Abx | WT | 3.24 | 5.96 | nd | nd | |
| 57 | Abx | WT | 2.82 | 5.96 | nd | nd | |
| 58 | Abx | ASO | 5.19 | 6.91 | 8.62 | 1 | |
| 59 | Abx | ASO | 4.64 | 7.49 | 3.36 | 1 | |
| 60 | Abx | ASO | 4.66 | 4.22 | 14.59 | 1 | |
| 61 | Abx | ASO | 6.07 | 5.49 | 6.24 | 0 | |
| 62 | Abx | ASO | 4.69 | 8.7 | 14.42 | nd | |
| 63 | Abx | ASO | 5.97 | 4.81 | 5.4 | nd | |
| 64 | Abx | ASO | 7.02 | 4.35 | 9.19 | nd | |
| 65 | Abx | ASO | 4.27 | 6.65 | 4.81 | nd | |
| 66 | Abx | ASO | 3.77 | 7.25 | 6.87 | nd | |
| 67 | Abx | ASO | 4 | 8.95 | 1.51 | nd | |
| 68 | Abx | ASO | 3.65 | 7.27 | 1.92 | nd | |
| 69 | ExGF | WT | 4.24 | 4.01 | 1.74 | 0 | |
| 70 | ExGF | WT | 4.63 | 6.53 | 3.19 | 0 | |
| 71 | ExGF | WT | 4.41 | 3.02 | 1.55 | 0 | |
| 72 | ExGF | WT | 4.84 | 5.16 | 3.15 | 0 | |
| 73 | ExGF | WT | 4.55 | 4.33 | 5.36 | nd | |
| 74 | ExGF | WT | 4.39 | 8.25 | 1.31 | nd | |
| 75 | ExGF | WT | 4.56 | 2.02 | 1.56 | nd | |
| 76 | ExGF | WT | 3.59 | 2.59 | 3.42 | nd | |
| 77 | ExGF | WT | 2.99 | 5.65 | 2.53 | nd | |
| 78 | ExGF | WT | 2.76 | 4.93 | 2.44 | nd | |
| 79 | ExGF | ASO | 8.49 | 18.31 | 11.72 | 1 | |
| 80 | ExGF | ASO | 9.18 | 7.39 | 2.7 | 1 | |
| 81 | ExGF | ASO | 5.27 | 9.27 | 21.26 | 1 | |
| 82 | ExGF | ASO | 6.49 | 10.04 | 1.63 | 1 | |
| 83 | ExGF | ASO | 8.07 | 4.63 | 2.4 | 2 | |
| 84 | ExGF | ASO | 8.17 | 9.29 | 8.18 | nd | |
| 85 | ExGF | ASO | 6.89 | 8.97 | 20.72 | nd | |
| 86 | ExGF | ASO | 6.82 | 8.24 | 4.52 | nd | |
| 87 | ExGF | ASO | 5.61 | 22.67 | 9.81 | nd | |
| 88 | ExGF | ASO | 6.26 | 6.87 | 7.36 | nd | |
| 89 | ExGF | ASO | 5.88 | 5.81 | 2.19 | nd | |
| 90 | ExGF | ASO | 4.54 | 5.37 | 11 | nd | |
| 91 | ExGF | ASO | 4.71 | 5.64 | 22.28 | nd | |
| 92 | ExGF | ASO | 8.06 | 8.67 | 16.78 | nd | |
| 93 | SCFA | WT | 8.51 | 4.84 | 1.79 | 0 | |
| 94 | SCFA | WT | 4.65 | 9.51 | 1.46 | 0 | |
| 95 | SCFA | WT | 4.89 | 3.68 | 1.4 | 0 | |
| 96 | SCFA | WT | 4.14 | 4.27 | 3.635 | 0 | |
| 97 | SCFA | WT | 3.23 | 7.60 | 1.55 | 0 | |
| 98 | SCFA | WT | 4.31 | 4.61 | 2.15 | 1 | |
| 99 | SCFA | ASO | 5.3 | 13.86 | 3.49 | 1 | |
| 100 | SCFA | ASO | 8.49 | 11.26 | 14.81 | 1 |
1–100 of 106
Rows per page:
1 / 2
Motor Function in α-Synuclein Mice Across Gut Microbiome Treatments — AI Analysis
Key Findings
- Germ-free α-synuclein mice performed nearly identically to wild-type controls across all 4 motor tests, with beam time of 5.3s vs 5.2s
- SPF (normal microbiome) ASO mice took 65% longer to cross the beam (7.9s vs 4.8s) and 99% longer to descend the pole (12.3s vs 6.2s)
- Antibiotic treatment protected ASO mice similarly to germ-free conditions: pole descent was just 6.6s vs 6.4s for WT
- Re-colonizing germ-free mice (ExGF) partially restored deficits: adhesive removal jumped to 10.2s in ASO vs 2.6s in WT — the largest gap of any test
- Hindlimb clasping scores followed the same pattern: SPF ASO mice scored 1.4/3 vs 0.17 for WT, while germ-free ASO scored just 0.5
Visualizations
Adhesive Removal Time by Treatment
Motor Deficit Ratio (ASO ÷ Wild-Type)
Pole Descent Time by Treatment
Beam Traverse Time by Treatment
Microbiome metabolites are sufficient
Short-chain fatty acids (SCFAs) alone — without live bacteria — reproduced motor deficits in germ-free ASO mice. SCFA-treated ASO mice were 1.9x slower on the beam and 2.2x slower on the pole than wild-type, matching SPF levels. This suggests microbial metabolites, not the bacteria themselves, drive α-synuclein-mediated motor pathology.